**Oral Metformin May Exacerbate Diabetic Neuropathy: A Two-Sample Mendelian Randomization Study**

Abstract:

Objective: Given the important role of metformin in diabetes treatment and the uncertainty regarding its relationship with diabetic neuropathy, this study aims to assess the causal relationship between metformin and diabetic neuropathy using Mendelian randomization.Methods: Instrumental variables were derived from publicly available genome-wide association study datasets. Two study cohorts were assigned: a training cohort (exposure ID: ukb-a-159) and a testing cohort (ID: ukb-b-14609), with the outcome ID being finn-b-DM_NEUROPATHY for both. The primary analysis used inverse variance weighting (IVW) for Mendelian randomization, supplemented by weighted median (WMed), weighted mode (WM), simple mode (SM), and MR Egger regression (MER). To test for heterogeneity, pleiotropy, and publication bias, we conducted leave-one-out sensitivity analyses, MR Egger regression, and further assessed with funnel plots.Results: Mendelian randomization analysis showed a significant positive causal relationship between metformin and diabetic neuropathy in both the training set (IVW: logOR 14.73, 95% CI [9.60, 19.86], p=1.78E-08) and the testing set (IVW: logOR 15.83, 95% CI [11.10, 20.56], p=5.54E-11). The WMed, WM, SM, and MER models all consistently supported this conclusion, with no evidence of pleiotropy or heterogeneity, indicating robust results.Conclusion: From an epidemiological perspective, this study reveals a significant positive correlation between metformin

use and diabetic neuropathy through Mendelian randomization analysis. This finding not only provides new insights into the field of diabetes treatment but also suggests that the use of metformin may be associated with the potential side effect of increased risk of diabetic neuropathy.

Keywords: Metformin, Diabetic Neuropathy, Mendelian Randomization, Epidemiology, Causal Relationship

**Background**

Diabetic neuropathy is one of the most common chronic microvascular complications of diabetes, affecting cranial nerves, central nerves, and peripheral nerves, and resulting in symptoms such as numbness, pain, decreased sensation, and muscle atrophy in the distal limbs[1]. The onset of diabetic neuropathy is insidious and progresses slowly, yet it severely impacts patients' quality of life. Its pathogenesis is closely related to metabolic disorders caused by hyperglycemia, damage to neurotrophic microvessels, and neurotrophic disorders[2]. Despite the availability of various treatment methods, the prevention and treatment of diabetic neuropathy remain suboptimal[3], necessitating new therapeutic strategies to slow disease progression.

Metformin, which was formally introduced into clinical practice in 1957, has become the first-line treatment for type 2 diabetes[4]. It not only effectively reduces blood glucose levels but also offers multiple benefits, including cardiovascular protection and improved insulin resistance[4]. Despite the broad benefits of metformin in diabetes treatment, its relationship with diabetic neuropathy remains controversial[5]. Some studies have suggested that metformin use may be associated with a reduced risk of

diabetic neuropathy, potentially due to its effects on improving insulin resistance, lowering blood glucose levels, and exerting anti-inflammatory and antioxidant actions[6]. However, other studies have proposed that long-term use of metformin may have adverse effects on the nervous system, especially at high doses and in specific patient populations (e.g., patients under 60 years of age with fewer comorbidities)[8]. These conflicting results suggest that the relationship between metformin and diabetic neuropathy may be influenced by multiple factors, including genetic background, drug dosage[9], treatment duration[10], and overall patient health status[8].

Given the important role of metformin in diabetes treatment and the uncertainty regarding its relationship with diabetic neuropathy, this study aims to assess the causal relationship between metformin and diabetic neuropathy using Mendelian randomization (MR). By leveraging genetic variants as instrumental variables (IVs), this study seeks to minimize the impact of confounding factors and more accurately evaluate the effect of metformin on the risk of diabetic neuropathy. This will provide new evidence and guidance for the application of metformin in the prevention and treatment of diabetic neuropathy.

**1 Methods and Materials**

This study is a secondary data review of existing databases. MR is a method that uses genetic variants of exposure as instrumental variables (IVs) to identify causal relationships between exposure phenotypes and outcomes. It leverages publicly available datasets from large-scale genome-wide association studies (GWAS) for "exposure" and "outcome" and overcomes typical limitations of observational studies.

It is a statistical method based on whole-genome sequencing data, designed to reveal

causal relationships. It is based on three core assumptions: 1) Relevance assumption (or

correlation assumption): Genetic variants (single nucleotide polymorphisms, SNPs)

must have a strong association with the exposure factor under study, ensuring that the

selected genetic variants can serve as effective proxy variables for the exposure[11]. 2)

Independence assumption: The instrumental variables (i.e., genetic variants) must be

independent of any known or unknown confounding factors to avoid interference from

confounders in the causal relationship, ensuring that the inferred causal relationship is

accurate[12]. 3) Exclusivity assumption: Genetic variants can only affect the outcome

through the exposure factor and not through other direct causal pathways, ensuring that

the impact of genetic variants on the outcome is entirely mediated through the exposure

factor, thereby accurately inferring the causal relationship between the exposure factor

and the outcome[13].

**1.1 Data Sources**

In MR analyses, UKB and FinnGen are two frequently mentioned large-scale databases

or cohort studies that provide valuable data resources for MR analysis[14]. UKB, the

UK Biobank, is a large cohort study comprising hundreds of thousands of

individuals[15]. It provides rich individual-level data, including genomic data, clinical

data, and lifestyle data, which are of significant value for studying causal relationships

of various diseases and traits. In MR analysis, data from UKB are often used to validate

and analyze research results. Researchers can utilize the genomic data from UKB,

combined with GWAS data of exposure factors and outcomes, to conduct MR analysis

and assess the causal relationships between exposure factors and outcomes. The large scale of UKB data, along with its GWAS results for various diseases and traits, enables researchers to validate and analyze causal relationships in larger sample sizes, thereby enhancing the reliability and accuracy of the results.

FinnGen is a large-scale genome-wide association study cohort in Finland, aimed at identifying genetic variants associated with various diseases and traits through GWAS[16]. Similar to UKB, data from FinnGen can also be used for MR analysis. Researchers can use the genomic data and GWAS results from FinnGen, combined with data on exposure factors and outcomes, to evaluate causal relationships. FinnGen's data, characterized by high homogeneity and detailed phenotypic information, offer advantages in identifying genetic variants associated with diseases. Additionally, FinnGen provides rich publicly available data, making it easier for researchers to access and use these data. The selection of appropriate databases or cohort studies is crucial in MR analysis. UKB and FinnGen, as two large-scale, high-quality databases, provide reliable data support for MR analysis.

In this study, we utilized two cohorts derived from the UK Biobank (UKB), focusing on patients using metformin as the exposure factor. The unique identifiers (IDs) of the two datasets were ukb-a-159 and ukb-b-14609, respectively. The data for the ukb-a-159 cohort originated from a study led by Professor Neale in 2017, which analyzed 10,894,596 single nucleotide polymorphisms (SNPs) based on over 337,000 samples, using the HG19/GRCh37 human genome build as the reference standard[17].

The other dataset, ukb-b-14609, was derived from a GWAS conducted by Ben

Elsworth et al. in 2018, involving 454,805 samples and 9,851,867 SNPs, also using the

HG19/GRCh37 human genome reference sequence[17]. Notably, both studies focused

on European populations, ensuring the homogeneity and comparability of the data. In

this study, the ukb-a-159 cohort was used as the training set to construct and validate

our analysis model, while the ukb-b-14609 cohort served as the testing set to evaluate

the model's predictive performance.

Additionally, to investigate diabetic neuropathy as the outcome, we incorporated cohort

data from the FinnGen database, with the ID finn-b-DM_NEUROPATHY. This was a

binary classification study focused on diabetic neuropathy, involving 1,415 case

individuals and 162,201 control individuals, analyzing 16,380,195 SNPs. The study

also used the HG19/GRCh37 human genome reference sequence, ensuring consistency

and comparability of the data[18].This study is a secondary data review utilizing

existing databases. Therefore, no additional ethical approvals were required.

**1.2 Selection of SNPs for Exposure and Outcome**

Extracting high-quality genetic variables is a key step in Mendelian randomization

studies to avoid interference from reverse causation and confounding factors. By

setting reasonable and stringent significance thresholds and implementing clumping

processes, the selected variables can have strong associations with the exposure factor

while being relatively independent of each other, thereby enhancing the accuracy and

reliability of Mendelian randomization studies[19]. For the exposure factor, a widely

accepted significance threshold of $p < 5×10^{-8}$ was used, meaning that only SNPs with

a p-value less than $5×10^{-8}$ in GWAS would be selected as instrumental variables. This

threshold ensures that the selected SNPs have sufficient statistical significance[20].

During the clumping process, a linkage disequilibrium (LD) threshold of $r² = 0.001$ was

used, meaning that any two SNPs with an $r²$ value greater than 0.001 would be

considered highly correlated, and only one would be retained in the same clump. A

physical distance threshold of $kb = 10000$ was applied, meaning that within a genomic

distance of 10,000 kb (i.e., 10 Mb), only the SNP with the smallest p-value would be

retained, while others would be removed as highly correlated.

**1.3 Statistical Analysis**

The two-sample MR analysis was conducted using R software (version 4.4.2) and the

TwoSampleMR package (version 0.6.8). In Mendelian randomization analysis, the

Inverse Variance Weighting (IVW) model was the primary analytical method.

Additionally, several other methods were employed to estimate causal effects,

including Weighted Median (WMed), MR-Egger regression (MER), Simple Model

(SM), and Weighted Model (WM). These methods were used as supplementary

approaches to provide a more comprehensive assessment of causal effects.

The mr function from the TwoSampleMR package was used to perform Mendelian

randomization analysis, identifying pairs with more than 10 eligible SNPs [20, 21]. The

analysis calculated the effect estimates (b-values) of exposure on outcomes, their

standard errors (SE), p-values, and log odds ratios (Log(OR)) with confidence intervals.

The mr_egger_regression function was used to test for heterogeneity and assess

pleiotropy through intercept analysis. If pleiotropy was detected, the interpretation of results would become complex, making it difficult to determine whether the outcome (diabetic neuropathy) was caused by the exposure (metformin), rendering the study inconclusive. If the heterogeneity test showed $p < 0.05$, a random-effects model was used in subsequent analyses; otherwise, a fixed-effects model was applied. Leave-One-Out (LOO) sensitivity analysis was conducted to evaluate the stability of the Mendelian randomization results by sequentially excluding instrumental variables. Publication bias was further assessed using funnel plots. The F-statistic was calculated to estimate weak instrument bias, with $F < 10$ indicating potential bias [22]. The analysis results were exported to Excel and PDF files, including forest plots, pleiotropy plots, sensitivity analysis plots, and funnel plots.

**2 Results**

### 2.1 Training Set Analysis: The Relationship Between Metformin and Diabetic Neuropathy

In the training set MR study, 45 SNPs were identified in common between the exposure (ID: ukb-b-14609) and the outcome. None of these SNPs were palindromic with intermediate allele frequencies. However, it is worth noting that 2 original target SNPs were missing in the target GWAS dataset. To compensate for this deficiency, we extracted proxy SNPs that were highly linked to these missing SNPs based on linkage disequilibrium (LD, $r^2=0.001$) to ensure the capture of the same genetic information.

After this step, a total of 45 SNPs were retained for subsequent analysis (see

Supplementary Material 1).

The MRE regression heterogeneity test results showed significant heterogeneity in our

data (Q=120.1205042, Q_pval=3.23E-09) (see Supplementary Material 2). To further

understand this heterogeneity, we drew and analyzed single SNP forest plots (see

Figure 1-1-A), leave-one-out sensitivity test forest plots (see Figure 1-1-B), and funnel

plots (see Figure 1-1-C). In these detailed analyses, we found that the results of the

target SNP rs9273268 were significantly deviated (pval.outcome=4.00313E-21). It

should be noted that rs9273268 was included in this analysis through its proxy SNP

rs17612496 (see Supplementary Material 3). Given that the significant deviation of

rs9273268 may have an adverse effect on the overall results, we cautiously decided to

exclude it from subsequent analyses. Therefore, the final number of SNPs used for

analysis was 44 (see Supplementary Material 4).

Figure 1-1-A                               Figure 1-1-B

Figure 1-1-C

Figure 1-1-A: Forest plot of single SNPs in the training set analysis before excluding rs9273268.

Figure 1-1-B: Leave-one-out sensitivity test forest plot in the training set analysis before excluding rs9273268.

Figure 1-1-C: Funnel plot in the training set analysis before excluding rs9273268.

After excluding rs9273268, we performed MRE regression analysis again, and the results did not show significant heterogeneity (Q=48.87, Q_pval=0.22) (see Supplementary Material 5). Based on this result, we used the fixed-effect model in the IVW analysis. The IVW analysis results also revealed a significant positive causal relationship between metformin and diabetic neuropathy (logOR=15.83, 95% CI [11.10, 20.56], p=5.54E-11). In addition, WMed analysis (OR=15.80, 95% CI [7.68, 23.91], p=1.36E-04), WM analysis (logOR=16.76, 95% CI [7.64, 25.89], p=8.17E-04), SM analysis (logOR=21.48, 95% CI [7.62, 35.33], p=4.04E-03), and MER analysis (logOR=15.62, 95% CI [1.73, 29.50], p=3.30E-02) all consistently supported a significant positive causal relationship between metformin and diabetic neuropathy (see Figure 1-2). LOO sensitivity test further confirmed the robustness of these results (see Figure 1-2-A). In addition, the results of MR-Egger regression analysis

(intercept=6.63E-04, se=0.02, p=0.97) did not reveal evidence of pleiotropy (see Figure

1-2-B).

Figure 1-2

| exposure | outcome | Number of SNPs | Model | logOR | Forest Plot | 95%CI | |
|---|---|---|---|---|---|---|---|
| ukb-b-14609 ( Treatment/m edication code: metformin) | finn-b-DM_NEUROPATHY (Diabetic neuropathy) | 44 | WM | 16.76 | | 7.64 | 25.89 |
| | | | WMed model | 15.80 | | 7.68 | 23.91 |
| | | | SM | 21.48 | | 7.62 | 35.33 |
| | | | MER model | 15.62 | | 1.73 | 29.50 |
| | | | IVW model | 15.83 | | 9.60 | 19.86 |

Figure 1-2: Forest plots of five analysis models (IVW, WMed, WM, SM, MER) in

the training set after excluding rs9273268

Figure 1-2-A                                    Figure 1-2-B

Figure 1-2-A: Leave-one-out sensitivity test forest plot in the training set analysis

after excluding rs9273268.

Figure 1-2-B: Scatter plot of pleiotropy in the training set after excluding rs9273268.

## 2.2 Test Set Analysis: The Relationship Between Metformin and Diabetic Neuropathy

In the test set MR study, 26 SNPs were identified in common between the exposure (ID: ukb-a-159) and the outcome. Two SNPs (rs649698 and rs649698) were removed due to being palindromic with intermediate allele frequencies, leaving 24 SNPs for analysis (see Supplementary Material 6). The MR Egger regression test showed no evidence of significant heterogeneity (Q=27.01, Q_pval=0.26) (see Supplementary Material 7), so the fixed-effect model was used in the IVW analysis. The IVW analysis found a significant positive causal relationship between metformin and diabetic neuropathy (logOR=14.73, 95% CI [9.60, 19.86], p=1.78E-08), which was supported by WMed (OR=14.92, 95% CI [7.32, 22.52], p=1.19E-04), WM (logOR=14.98, 95% CI [6.48, 23.47], p=2.16E-03), SM (logOR=15.41, 95% CI [3.01, 27.80], p=2.30E-02), and MER (logOR=14.29, 95% CI [0.75, 27.82], p=5.05E-02) analyses (see Figure 2-1). LOO sensitivity test confirmed the robustness of the results (see Figure 2-2-A). In the MR-Egger regression (intercept=4.25E-04, se=0.02, p=0.99), no pleiotropy was found (see Figure 2-2-B).

Figure 2-1

| exposure | outcome | Number of SNPs | Model | logOR | Forest Plot | 95%CI | |
|---|---|---|---|---|---|---|---|
| id:ukb-a-159 (Treatment/medication code: metformin) | id:finn-b-DM_NEUROPATHY (Diabetic neuropathy) | 25 | WM | 14.98 | | 6.48 | 23.47 |
| | | | WMed model | 14.92 | | 7.32 | 22.52 |
| | | | SM | 15.41 | | 3.01 | 27.80 |
| | | | MER model | 14.29 | | 0.75 | 27.82 |
| | | | IVW model | 14.73 | | 9.60 | 19.86 |

Figure 2-1: Forest plots of five analysis models (IVW, WMed, WM, SM, MER) in the test set.

Figure 2-2-A                             Figure 2-2-B

Figure 2-2-A: Leave-one-out sensitivity test forest plot in the test set.

Figure 2-2-B: Scatter plot of pleiotropy in the test set.

## 3 Discussion

Mendelian randomization (MR) has gained widespread attention and application in public health and medicine in recent years as an innovative epidemiological method. By leveraging genetic variants as instrumental variables, MR explores the potential causal relationships between diseases and exposures. Compared to traditional observational studies, MR effectively avoids common issues such as confounding bias

and reverse causation, significantly enhancing the reliability and accuracy of findings. This is because genetic variants are randomly distributed in the population, free from the interference of external confounding factors, thus simulating a naturally occurring randomized controlled trial.

In this study, we used the MR method to investigate the causal relationship between metformin and diabetic neuropathy. The IVW analysis in the training set strongly supported a significant positive causal relationship between metformin and diabetic neuropathy. This conclusion was further validated in multiple analytical models, including WMed, WM, SM, and MER, demonstrating high robustness. LOO sensitivity analysis also confirmed the reliability of these findings. Additionally, MR-Egger regression showed no evidence of pleiotropy or heterogeneity, further strengthening our confidence in the conclusion.

In the testing set, we observed a significant positive association between metformin and diabetic neuropathy, which remained consistent and stable across various analytical methods and sensitivity tests. Although metformin is a standard treatment for type 2 diabetes, with significant clinical value in controlling blood glucose levels and potentially delaying neuropathy progression, our results suggest that metformin use may also increase the risk of diabetic neuropathy.

Our findings are consistent with previous cohort studies. According to Serra MC et al., compared to patients treated with metformin for at least 6 months but less than 18 months, veterans aged 50 years or older treated with metformin for at least 18 months had a significantly higher risk of diabetic peripheral neuropathy (DPN), approximately

2-3 times higher [10]. Hashem et al. found in a prospective clinical study that metformin use was associated with exacerbated DPN, especially within the first 6 months of treatment and more prominently in high-dose groups [9]. Hussain et al. [23] further explored this phenomenon, suggesting that metformin may lead to vitamin B12 (cobalamin) deficiency by interfering with calcium-dependent membrane activity and altering gut microbiota. Vitamin B12 deficiency can subsequently cause progressive demyelination, peripheral neuropathy, and hematological abnormalities. Moore et al. [7] also noted that metformin use may be associated with cognitive impairment. These findings highlight the importance of routine monitoring, early detection, and personalized intervention measures when using metformin to treat diabetes.

From an epidemiological perspective, our results suggest a significant link between metformin use and an increased risk of diabetic neuropathy. Biologically, this conclusion may be closely related to vitamin B12 deficiency caused by metformin use. Therefore, we recommend closely monitoring vitamin B12 levels in patients using metformin. Patients with borderline vitamin B12 levels should regularly test for methylmalonic acid and homocysteine to detect vitamin B12 deficiency early and take appropriate measures, including timely supplementation. However, we cannot rule out the potential role of other biological mechanisms in the association between metformin and diabetic neuropathy, and further in-depth research is needed.

Despite the strengths in design and methodology, our study has some limitations. For example, the selection of SNPs and the use of proxy SNPs may be influenced by factors such as linkage disequilibrium, sample size, and population differences. Future studies

should consider these factors and explore more precise and comprehensive methods to assess the relationship between metformin and diabetic neuropathy, providing more reliable guidance for clinical practice.

**4 Conclusion**

Using the innovative epidemiological method of Mendelian randomization, this study explored the potential causal relationship between metformin and diabetic neuropathy. Through rigorous data analysis and validation using multiple analytical models, we concluded that there is a significant positive association between metformin use and diabetic neuropathy. This finding not only provides a new perspective on the role of metformin in diabetes treatment but also highlights a potential adverse effect of metformin, specifically the increased risk of diabetic neuropathy. Future research should further investigate the underlying mechanisms of this relationship and assess the risks and benefits of metformin use in different patient populations.

Acknowledgements

We sincerely thank all the participants who generously provided their data, and the researchers and scientists for their commitment to collecting and sharing summary-level data from GWAS.

Authors' contributions

Data curation, Yuanjin Chen, Jiaoling Shi and Jueying Chen; formal analysis, Ningning Ma; project management, Xiaoyong Wang and Yujuan Wu; writing - original draft, Xiaoyong Wang.

Data availability

All data generated or analysed in this study are included in the published article [and its

Supplementary Information files].

Declarations

Competing interests

The authors declare no competing interests.

Contributor information

Xiaoyong Wang, e-mail: wxy00163@163.com

*Corresponding author: Yujuan Wu, email: wyj00163@163.com

References:

[1]. Yapislar, H. and E.B. Gurler, Management of Microcomplications of Diabetes

Mellitus: Challenges, Current   Trends, and Future Perspectives in Treatment.

Biomedicines, 2024. 12(9).

[2]. Elafros, M.A., et al., Towards prevention of diabetic peripheral neuropathy:

clinical presentation,   pathogenesis, and new treatments. Lancet Neurol, 2022. 21(10):

p. 922-936.

[3]. Mallick-Searle, T. and J.A. Adler, Update on Treating Painful Diabetic

Peripheral Neuropathy: A Review of Current US   Guidelines with a Focus on the Most

Recently Approved Management Options. J Pain Res, 2024. 17: p. 1005-1028.

[4]. Bailey, C.J., Metformin: Therapeutic profile in the treatment of type 2 diabetes.

Diabetes, obesity & metabolism, 2024. 26(S3): p. 3-19.

[5]. Tabatabaei, M.O., et al., The effect of metformin on cognitive function: A

systematic review and meta-analysis. J Psychopharmacol, 2022. 36(6): p. 666-679.

[6]. Dhanapalaratnam, R., et al., Effect of Metformin on Peripheral Nerve Morphology in Type 2 Diabetes: A Cross-Sectional Observational Study. Diabetes (New York, N.Y.), 2024. 73(11): p. 1875-1882.

[7]. Moore, E.M., et al., Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care, 2013. 36(10): p. 2981-2987.

[8]. Yang, R., et al., Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China. Front Endocrinol (Lausanne), 2023. 14: p. 1082720.

[9]. Hashem, M.M., et al., The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus. Scientific reports, 2021. 11(1): p. 1940-1940.

[10]. Serra, M.C., et al., Long-term metformin treatment and risk of peripheral neuropathy in older Veterans. Diabetes research and clinical practice, 2020. 170: p. 108486-108486.

[11]. Smith, G.D. and S. Ebrahim, Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol, 2004. 33(1): p. 30-42.

[12]. Lawlor, D.A., et al., Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med, 2008. 27(8): p. 1133-63.

[13]. Davey Smith, G. and G. Hemani, Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Human molecular genetics, 2014. 23(R1): p. R89-R98.

[14].   Dai, L., et al., Identifying prioritization of therapeutic targets for ankylosing spondylitis: a  multi-omics Mendelian randomization study. J Transl Med, 2024. 22(1): p. 1115.

[15].   Allen, N.E., et al., Prospective study design and data analysis in UK Biobank. Science Translational Medicine, 2024. 16(729).

[16].   Kurki, M.I., et al., FinnGen provides genetic insights from a well-phenotyped isolated population. Nature, 2023. 613(7944): p. 508-518.

[17].   Zhang, Z., et al., Bridging the gap: exploring the causal relationship between metformin and tumors. Frontiers in Genetics, 2024. 15.

[18].   Liu, Q., et al., Evaluation of bi-directional causal association between obstructive sleep apnoea  syndrome and diabetic microangiopathy: a Mendelian randomization study. Front Cardiovasc Med, 2024. 11: p. 1340602.

[19].   Zheng, J., et al., Phenome-wide Mendelian randomization mapping the influence of the plasma proteome  on complex diseases. Nat Genet, 2020. 52(10): p. 1122-1131.

[20].   Savage, J.E., et al., Genome-wide association meta-analysis in 269,867 individuals identifies new  genetic and functional links to intelligence. Nat Genet, 2018. 50(7): p. 912-919.

[21].   Gao, X., et al., The bidirectional causal relationships of insomnia with five major psychiatric  disorders: A Mendelian randomization study. Eur Psychiatry, 2019. 60: p. 79-85.

[22].   Pierce, B.L., H. Ahsan and T.J. Vanderweele, Power and instrument strength

requirements for Mendelian randomization studies   using multiple genetic variants. Int J Epidemiol, 2011. 40(3): p. 740-52.

[23].    Hussain, M.S., et al., Long-Term Use of Metformin and Vitamin B12 Deficiency in Diabetes. Curr Drug Saf, 2024.

MR effect size for
'Treatment/medication code: metformin || id:ukb−b−14609' on 'Diabetic neuropathy || id:finn−b−DM_NEUROPATHY'

MR effect size for
'Treatment/medication code: metformin || id:ukb−b−14609' on 'Diabetic neuropathy || id:finn−b−DM_NEUROPATHY'

| exposure | outcome | Number of SNPs | Model | logOR | Forest Plot | 95%CI | |
|---|---|---|---|---|---|---|---|
| | | | WM | 16.76 | | 7.64 | 25.89 |
| | | | WMed model | 15.80 | | 7.68 | 23.91 |
| ukb-b-14609 （Treatment/m edication code: metformin） | finn-b-DM_NEUROPATHY (Diabetic neuropathy) | 44 | SM | 21.48 | | 7.62 | 35.33 |
| | | | MER model | 15.62 | | 1.73 | 29.50 |
| | | | IVW model | 15.83 | | 9.60 | 19.86 |

| pval |
| --- |
| 8.17E-04 |
| 1.36E-04 |
| 4.04E-03 |
| 3.30E-02 |
| 1.78E-08 |

MR effect size for
'Treatment/medication code: metformin || id:ukb−b−14609' on 'Diabetic neuropathy || id:finn−b−DM_NEUROPATHY'

| exposure | outcome | Number of SNPs | Model | logOR | Forest Plot | 95%CI | |
|---|---|---|---|---|---|---|---|
| id:ukb-a-159 （Treatment/medication code: metformin） | id:finn-b-DM_NEUROPATHY (Diabetic neuropathy) | 25 | WM | 14.98 | | 6.48 | 23.47 |
| | | | WMed model | 14.92 | | 7.32 | 22.52 |
| | | | SM | 15.41 | | 3.01 | 27.80 |
| | | | MER model | 14.29 | | 0.75 | 27.82 |
| | | | IVW model | 14.73 | | 9.60 | 19.86 |

| pval |
| --- |
| 2.16E-03 |
| 1.19E-04 |
| 2.30E-02 |
| 5.05E-02 |
| 1.78E-08 |

MR effect size for
'Treatment/medication code: metformin || id:ukb−a−159' on 'Diabetic neuropathy || id:finn−b−DM_NEUROPATHY'